Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03962998
Recruitment Status : Recruiting
First Posted : May 24, 2019
Last Update Posted : January 9, 2020
Sponsor:
Information provided by (Responsible Party):
MediBeacon

Brief Summary:
The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).

Condition or disease Intervention/treatment Phase
Crohn Disease Drug: Lactulose/Rhamnose solution Drug: MB-102 Early Phase 1

Detailed Description:
This study is a single center, randomized, open label, cross-over study evaluating MB-102 versus dual sugar testing using lactulose and rhamnose for the assessment of gut permeability. Participants will be screened within 30 days of Day 1, and eligible participants will be randomized to receive either an oral dose of MB-102 or the dual sugar test on Day 1. At a second study visit occurring between 3 to 7 days after completion of the first test, participants will return to the study center for the second test. Following completion of the second test, participants will return to the study center 7 ±3 days for a follow-up visit to evaluate safety.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Randomized Unblinded Feasibility Study Evaluating the Use of Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability in Normal Subjects and Subjects With Active Small Bowel Crohn's Disease
Actual Study Start Date : October 27, 2019
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Lactulose

Arm Intervention/treatment
Active Comparator: Lactulose/Rhamnose
1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution
Drug: Lactulose/Rhamnose solution
Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine

Experimental: MB-102
4 μmol of MB-102/kg body weight administered orally as a solution
Drug: MB-102
MB-102 solution administered orally followed by measurement of excreted MB-102 in urine




Primary Outcome Measures :
  1. Mean urine concentration of MB-102 over time in normal participants and in those with Crohn's disease [ Time Frame: Pre-dose and 1, 2, 4, 6, 8, 10, and 12 hours ]
    Urine samples will be collected pre-dose (time 0), each time the participant voids, and at the protocol-defined time points after oral administration of MB-102. The total volume of urine excreted will be recorded. Urine samples will be analyzed using validated analytical methods.


Secondary Outcome Measures :
  1. Correlation between MB-102 excretion and the results of dual sugar testing in normal participants and in those with Crohn's disease [ Time Frame: Pre-dose and 1, 2, 4, 6, 8, 10, and 12 hours ]
    For MB-102 excretion evaluation, urine samples will be collected pre-dose (time 0), each time the participant voids, and at the protocol-defined time points after oral administration of MB-102. The total volume of urine excreted will be recorded. Urine samples will be analyzed using validated analytical methods. For the dual sugar test, participants will consume a 10 mL solution (1000 mg of lactulose and 200 mg of rhamnose). Urine will be collected pre-dose (time 0), each time the participant voids, and at the protocol-defined time points after consuming the sugar solution. The total volume of urine excreted will be recorded. Urine samples will be analyzed using validated analytical methods.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria for all participants:

  • Age > 18 years - male or non-pregnant or lactating females
  • Participants willing to comply with study requirements
  • Participants who have signed an informed consent form
  • Normal or non-clinically significant screening and baseline 12 lead electrocardiogram (ECG) in the opinion of the principal investigator (PI)
  • Estimated glomerulofiltration rate (eGFR) > 75 mL/min/1.73 m^2
  • Agreement to not utilize nonsteroidal anti-inflammatory drugs (NSAIDs) until study completion.

Inclusion criteria for participants with Crohn's disease:

  • Participants with active small bowel Crohn's disease diagnosed by an abnormal Magnetic Resonance Enterography (MRE) within 1 month prior to screening
  • Active Crohn's disease must be characterized by mucosal hyperemia, and/or bowel wall thickening and/or vascular engorgement

Exclusion criteria for all participants:

  • Women who are pregnant, lactating, or planning to become pregnant during the study, or women who are of childbearing potential unwilling to use an adequate method of birth control a. Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post dose
  • Participation in another interventional trial within 30 days of dosing or concurrently enrolled in any other medical research study which could impact the results of the study
  • Unable to tolerate an overnight fast
  • NSAID use within 14 days of Day 1
  • History of drug or alcohol abuse within the past year
  • Diagnosis of ulcerative colitis, indeterminate colitis, pseudomembranous colitis, or celiac disease
  • Prior or current diagnosis of an autoimmune disease
  • Gastrointestinal surgery (including appendectomy) within 12 weeks prior to screening or has surgery planned or deemed likely to require surgery during the study
  • Type 1 or 2 diabetes
  • History of severe allergic hypersensitivity reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, or MB-102 (intolerance to a drug is not considered a drug allergy)
  • Known history of testing positive for acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV)
  • Site personnel immediately associated with the study or their immediate family members
  • Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial
  • Prior exposure to MB-102
  • Any changes to chronic medication therapy or initiation of new medications between Testing Day 1 and Testing Day 2
  • Current urinary tract infection
  • Body mass index > 30 kg/m^2
  • Prior history of small bowel malignancy or resection surgery
  • Unable to meet the requirements of the study including 12+ hour study visits

Additional exclusion criteria for normal participants:

  • Fecal transplant within 1 year
  • Prior or current graft-vs.-host disease
  • Prior or current history of diverticulitis
  • Current or prior history of fatty liver
  • Current use of any biologic therapy or current use of the following medications: sulfasalazine, mesalamine, olsalazine, balsalazide, prednisone, cyclosporine, azathioprine, 6-mercaptopurine, tacrolimus, methotrexate, intravenous immunoglobulin, anti-diarrheal agents
  • Prior antibiotic therapy within 30 days of screening
  • Undiagnosed chronic gastrointestinal upset or food intolerance history
  • Recent history of significant unplanned weight loss, blood in the stool or acute episodes of diarrhea
  • First-degree relative (sibling, parent, child) has inflammatory bowel disease (Crohn's disease, ulcerative colitis, proctitis, indeterminate colitis)
  • History of Crohn's disease

Additional exclusion criterion for participants with Crohn's disease:

- Participant on Total Parenteral Nutrition (TPN)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03962998


Contacts
Layout table for location contacts
Contact: Richard B Dorshow, PhD 314-735-0967 rbdorshow@medibeacon.com

Locations
Layout table for location information
United States, Missouri
Washington University in St. Louis Recruiting
Saint Louis, Missouri, United States, 63110
Principal Investigator: Lori Holtz, MD         
Sponsors and Collaborators
MediBeacon
Investigators
Layout table for investigator information
Study Director: Richard B Dorshow, PhD MediBeacon
Layout table for additonal information
Responsible Party: MediBeacon
ClinicalTrials.gov Identifier: NCT03962998    
Other Study ID Numbers: MB-300-01
First Posted: May 24, 2019    Key Record Dates
Last Update Posted: January 9, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MediBeacon:
Gut permeability
Intestinal permeability
MB-102
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Lactulose
Gastrointestinal Agents